We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Value of Von Willebrand Factor in Portal Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01358123
Recruitment Status : Unknown
Verified September 2015 by Arnulf Ferlitsch, MD, Medical University of Vienna.
Recruitment status was:  Recruiting
First Posted : May 23, 2011
Last Update Posted : September 25, 2015
Information provided by (Responsible Party):

May 18, 2011
May 23, 2011
September 25, 2015
September 2006
May 2016   (Final data collection date for primary outcome measure)
von Willebrand Factor Ag Level [ Time Frame: at first visit (HVPG Measurement) (day 1) ]
von Willebrand Factor Antigen Levels are measured via ELISA and compared /corrlated to Hepatic Venous Pressure Gradient (HVPG). von Willebrand Factor Antigen levels are drawn and analyzed at the day of HVPG measurement. No follow up measurements will be performed, survival will be measured as secondary outcome parameter
Same as current
Complete list of historical versions of study NCT01358123 on ClinicalTrials.gov Archive Site
Overall Mortality [ Time Frame: 3 Months ]
Survival of Patients after index measurement of von Willebrand Factor and HVPG
Same as current
Not Provided
Not Provided
Value of Von Willebrand Factor in Portal Hypertension
Von Willebrand Factor As Non-Invasive Predictor Of Clinically Significant Portal Hypertension And Mortality In Patients With Liver Cirrhosis
In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag) are found frequently but the clinical significance is unclear. vWF-Ag plays an important role in primary haemostasis and development of thrombotic vascular obliteration is discussed as a possible mechanism leading to portal hypertension. Invasive measurement of hepatic venous pressure gradient (HVPG) is the current gold standard for the diagnosis of portal hypertension. The investigators hypothesize that vWF-Ag levels in plasma may correlate with portal pressure and predict clinically significant portal hypertension (CSPH, HVPG >=10mmHg) and its complications.
Patients with alcoholic, viral (chronic hepatitis C), and cryptogenic liver cirrhosis are included. Portal hemodynamics are assessed by HVPG measurement, vWF-Ag levels were measured by ELISA. Results will be compared. 3 and 6 months mortality will be recorded.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients with liver cirrhosis of all etioloiges, routinely scheduled for routine HVPG measurement will systematically be included during the study period
  • Liver Cirrhosis
  • Portal Hypertension
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
June 2016
May 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Liver cirrhosis

Exclusion Criteria:

  • no HVPG measurement
Sexes Eligible for Study: All
18 Years to 98 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Arnulf Ferlitsch, MD, Medical University of Vienna
Medical University of Vienna
Not Provided
Principal Investigator: Arnulf Ferlitsch, MD Medical University of Vienna
Medical University of Vienna
September 2015